Dallas Heart StudyLipid Characteristics of Blacks With Nonsense

Mutations in PCSK9

ARICPCSK9 Loss-of-Function Mutations, LDL-C, and

CHD Risk

PCSK9-Directed Therapies in Development

Effects of Evolocumab (AMG-145) on LDL-C Levels

Phase 1b Study Design

Evolocumab -- Phase 1bChange in LDL-C at 2- and 4-Week Dosing

Intervals on Statin Therapy

PCSK9 InhibitorsPhase 2

MENDELEvolocumab Phase 2 Monotherapy in Patients

With Hypercholesterolemia

MENDELStudy Design

MENDELEvolocumab Monotherapy for Hypercholesterolemia

PCSK9 InhibitorsPhase 2

Alirocumab (SAR236553) Add-on to Atorvastatin

AlirocumabChange in LDL-C at 2- and 4-Week Dosing Intervals on

Atorvastatin

Alirocumab on Top of Atorvastatin in Primary Hypercholesterolemia

LAPLACE-TIMI 57Evolocumab in Combination With Statin in

Patients With Hypercholesterolemia

LAPLACE-TIMI 57 Study Design

LAPLACE-TIMI 57 Effect of Evolocumab on Percentage Change in

LDL-C From Baseline

Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin

Therapy Phase 2 Studies

Intravenous RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy

Doses Studied

Intravenous RN316 in Hypercholesterolemic Patients on

High or Maximum-Dose Statin Therapy

Pooled Results

PCSK9 InhibitorsPhase 2

GAUSSPhase 2 Evolocumab in Statin-Intolerant Patients

GAUSSEvolocumab in Statin Intolerance

PCSK9 InhibitorsPhase 2

Effect of Alirocumab on LDL-C in Heterozygous FH

RUTHERFORDPhase 2 Evolocumab in Patients With

Heterozygous FH

RUTHERFORDEffect of Evolocumab on LDL-C in Heterozygous

FH

Phase 3 Trials

OSLER Phase 3 Extension Study

OSLEREffect of Evolocumab on LDL-C after 52 Weeks

ODYSSEY OutcomesPhase 3 Post-ACS With Alirocumab

References

References (cont)

References (cont)